Artelo Biosciences (NASDAQ:ARTL) Posts Quarterly Earnings Results, Misses Estimates By $0.43 EPS

Artelo Biosciences (NASDAQ:ARTL) posted its earnings results on Monday. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.43), Zacks reports.

Artelo Biosciences Stock Up 3.5 %

NASDAQ ARTL opened at $1.04 on Wednesday. Artelo Biosciences has a twelve month low of $0.91 and a twelve month high of $1.70. The firm has a market capitalization of $3.34 million, a PE ratio of -0.36 and a beta of 1.25. The stock’s 50 day moving average is $1.17 and its 200 day moving average is $1.16.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ARTL. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a research note on Wednesday, December 25th. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a research note on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Artelo Biosciences in a research note on Tuesday.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.